Sprott’s NervGen Pharma NGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$47.8K Hold
25,000
– – ﹤0.01% 249
2026
Q2
$51.5K Hold
25,000
– – ﹤0.01% 259
2026
Q1
$94.2K Buy
+25,000
New +$108K ﹤0.01% 228

Other funds holding NGEN

Sprott's NGEN Position: Q3 2026 in Review

Sprott held its NervGen Pharma (NGEN) position steady in Q3 2026 at 25,000 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #249.

Sprott first reported a position in NGEN in Q1 2026 and has held it in 3 quarters since. The position peaked at $94.2K in Q1 2026. 49 funds tracked by Wall St. Rank hold NGEN as of Q3 2026.

  • Sprott held 25,000 shares of NervGen Pharma worth $47.8K as of Q3 2026.
  • Sprott left its NervGen Pharma share count unchanged in Q3 2026.
  • NervGen Pharma made up ﹤0.01% of Sprott's portfolio in Q3 2026, its #249 holding.
  • Sprott first reported a position in NervGen Pharma in Q1 2026 and has held it in 3 quarters since.
  • Sprott's NervGen Pharma position peaked at $94.2K in Q1 2026.
  • 49 funds tracked by Wall St. Rank held NervGen Pharma as of Q3 2026.

Based on Sprott's 13F filing for Q3 2026, filed 9 Nov 2026.